Nantahala Capital Management LLC Acquires Shares of 5,475,040 Fulcrum Therapeutics, Inc. $FULC

Nantahala Capital Management LLC acquired a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,475,040 shares of the company’s stock, valued at approximately $20,038,646. Nantahala Capital Management LLC owned about 7.18% of Fulcrum Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at approximately $164,000. Jane Street Group LLC lifted its position in Fulcrum Therapeutics by 62.1% in the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after buying an additional 45,157 shares during the last quarter. Creative Planning bought a new stake in Fulcrum Therapeutics in the second quarter worth $117,000. Legal & General Group Plc boosted its stake in Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock worth $120,000 after buying an additional 12,173 shares during the period. Finally, American Century Companies Inc. boosted its stake in Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock worth $911,000 after buying an additional 8,638 shares during the period. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Shares of FULC stock opened at $3.85 on Friday. The stock has a 50 day moving average price of $3.73 and a 200 day moving average price of $6.00. Fulcrum Therapeutics, Inc. has a 52-week low of $2.83 and a 52-week high of $15.74. The firm has a market capitalization of $293.75 million, a P/E ratio of -3.18 and a beta of 3.05.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). As a group, sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.69 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on FULC. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target for the company. in a research note on Tuesday, June 2nd. HC Wainwright cut shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a report on Wednesday, June 3rd. Finally, Truist Financial lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $8.20.

Insider Buying and Selling

In related news, Director Alan Ezekowitz sold 18,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total value of $65,700.00. Following the transaction, the director owned 10,927 shares of the company’s stock, valued at $39,883.55. This trade represents a 62.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.30% of the stock is owned by corporate insiders.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.